Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cu 64 PSMA I&T - Curium Pharma

Next Previous
Drug Profile

Cu 64 PSMA I&T - Curium Pharma

Alternative Names: 64-Copper-PSMA-I&T - Curium; 64-Cu-PSMA-I&T; Copper-64 prostate specific membrane antigen I&T; Cu-64-PSMA-I&T

Latest Information Update: 11 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Curium Pharma
  • Class Antineoplastics; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 08 Jul 2025 PDRadiopharma files an IND application with the PMDA in Japan for Prostate cancer
  • 08 Jul 2025 PDRadiopharma plans a clinical trial in Prostate cancer (Diagnosis, Newly diagnosed) in Japan(IV)
  • 18 Feb 2025 Curium Pharma completes the phase III Solar-Recur trial for Prostate cancer (Diagnosis) in USA (IV, Injection) (NCT06235099)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top